Auna S.A.

Auna reported second-quarter results with revenue up 9% year over year on an FX-neutral basis, but adjusted EBITDA fell 9% amid margin pressure, talent investments and Peru billing penalties. Mexico patient volumes recovered, with surgeries up 7% sequentially and oncology chemotherapies and radiotherapies up 20% from the first quarter, while Colombia revenue rose 13% as the company expanded private-payer and risk-sharing contracts. Peru revenue increased 8%, though EBITDA was held flat by billing-related penalties and higher operating costs. Cash generation and leverage improved significantly: first-half operating cash flow rose 45%, free cash flow increased 181% and leverage declined to 3.6 times. Auna reaffirmed its outlook for roughly 12% FX-neutral revenue growth and adjusted EBITDA growth near the low end of its 10%-14% target range.

Auna reported second quarter adjusted net income of S/40 million, down from S/89 million a year earlier, citing foreign exchange-driven variance on net finance costs. Revenues rose 13% year over year to S/1,238 million, with local currency growth of 4% in Mexico, 8% in Peru, and 13% in Colombia. Adjusted EBITDA declined 6% to S/227 million, with an adjusted EBITDA margin of 18.4%, as segment adjusted EBITDA fell 16% in Mexico and 12% in Colombia in local currency. Adjusted net income per share was S/0.50 based on 74,237,368 weighted average basic and diluted shares.